The immuno-oncology therapy developer has amassed at least $190m of overall funding following a series B round backed by Lilly Asia Ventures.
US-based immuno-oncology therapy developer Synthekine has raised $108m in a series B round featuring Lilly Asia Ventures, a corporate venturing vehicle for pharmaceutical firm Eli Lilly. The round was co-led by investment firm Deerfield Management and asset manager Janus Henderson Investors. RA Capital Management, Rock Springs Capital, Omega Funds, Samsara BioCapital, Canaan Partners, Emerson Collective,…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.